Importance of screening and early detection of pulmonary hypertension and current treatment options.(Expert's Comments)

Byline: N Mohan

Pulmonary hypertension (PHT) usually a late-stage complication, is the greatest in quantity common cause of death in mixed connective tissue disease (MCTD) occurring in up to 38% of patients.[1] Since PHT does not become clinically manifest until advanced, flat mild elevations in pulmonary arterial compressing reflect diffuse and extensive vascular damage. [i]or[/i] part of to the other the mid-1980s median survival from the date of diagnosis was approximately 28 years. However, several novel therapeutic agents evolveed in recent years, have made early detection and monitoring imperative for